Prévisions

L'objectif de cours moyen des analystes est de 0,43 € (+498 161,88 %). La médiane est de 0,43 € (+498 161,88 %).

Acheter	3
Conserver	3
Vendre	0

Actualités Accéder au fil d'actualités

IO Biotech appoints Raymond James and announces significant job cuts

IO Biotech has appointed Raymond James & Associates as exclusive financial advisor to support the previously announced review of strategic alternatives. At the same time, the company announced substantial cost reductions, including significant workforce cuts, to preserve liquidity during the review. It did not disclose the number of employees affected or details of potential strategic options; data from InvestingPro point to rapid cash burn given a current ratio of 2.01. » Plus sur de.investing.com
IO Biotech stock falls after downgrade and announcement of strategic review

IO Biotech's stock dropped about 15% after Piper Sandler downgraded the rating from "Overweight" to "Neutral" and cut the price target from $3.00 to $0.50. The move was triggered by the company's announcement that it is reviewing various strategic options such as a merger, sale of assets or liquidation, without providing further details. The analyst justified the downgrade by citing uncertainty around the review process and ongoing cash constraints; the new price target is based on a net present value of roughly $0.20 per share plus a residual value for the pipeline. » Plus sur de.investing.com
IO Biotech: Promising 5-year data for melanoma vaccine show prolonged survival

IO Biotech publishes five-year follow-up data in Nature Communications on the IO102‑IO103 plus Nivolumab combination in metastatic melanoma, reporting a median progression-free survival of 25.5 months, a median overall survival of 60 months and a median duration of response of more than 53 months. The 30-patient study identified potential vaccine-specific immune biomarkers and confirms the FDA Breakthrough Therapy designation for the combination with Pembrolizumab. A parallel phase 3 trial has enrolled 407 patients, with initial results expected in Q3 2025, while the company reports financial constraints, has halved its workforce and expects cash reserves to last until Q1 2026. » Plus sur de.investing.com

Données financières de l'entreprise

Au dernier trimestre, IO BIOTECH INC. DL-,001 Aktie a réalisé un chiffre d'affaires de 0 € et un bénéfice net de -7,14 M €

(EUR)	sept. 2025	YoY
Chiffre d'affaires	0	-
Bénéfice brut	-195,99 k	-
Bénéfice net	-7,14 M	-
EBITDA	-7,61 M	-

Données fondamentales

Indicateur	Valeur
Capitalisation boursière	764,76 k €
Nombre d'actions	71,95 M
Plus haut/bas sur 52 semaines	2,41 € - 0,0106 €
Dividendes	Non
Bêta	0,89
Ratio P/E	-0,01
Ratio PEG	0,01
Ratio P/B	0,90
Ratio P/S	0,00

Profil de l'entreprise

IO Biotech, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase und entwickelt immunmodulierende Krebstherapien auf der Grundlage der T-win-Technologieplattform. Der führende Produktkandidat des Unternehmens, IO102-IO103, zielt auf immunsuppressive Proteine wie Indoleamin-2,3-Dehydrogenase (IDO) und den programmierten Todesliganden (PD-L1) ab und befindet sich in einer klinischen Studie der Phase 2 zur Behandlung von Melanomen sowie in einer klinischen Studie der Phase 1 zur Behandlung von Lungen-, Kopf- und Hals-, Blasen- und Melanomkrebs. Das Unternehmen entwickelt außerdem IO112, einen Produktkandidaten, der ein einzelnes, von Arginase 1 abgeleitetes Peptid enthält, das auf T-Zellen abzielt, die von Arginase 1 abgeleitete Epitope für die Behandlung von Krebserkrankungen erkennen. Das Unternehmen wurde im Jahr 2014 gegründet und hat seinen Sitz in Kopenhagen, Dänemark.

Nom	IO BIOTECH INC. DL-,001 Aktie
PDG	Mai-Britt Zocca
Siège social	Copenhagen, Danemark
Site web	iobiotech.com
Industrie	Produits chimiques
Introduction en bourse	05/11/2021
Employés	80